The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis

  • Cho, Yoon Young (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Joung, Ji Young (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jeong, Hyemin (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Je, Dongmo (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Hong, Yun Soo (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Suh, Sunghwan (Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine) ;
  • Kim, Sun Wook (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2012.06.19
  • Accepted : 2013.01.28
  • Published : 2013.11.01
⟨ Previous Next ⟩

Abstract

Both Graves disease and Guillain-Barre syndrome (GBS) are autoimmune disorders caused by impaired self-tolerance mechanisms and triggered by interactions between genetic and environmental factors. GBS in patients who suffer from other autoimmune diseases is rarely reported, and the development of postinfectious GBS in a patient with Graves disease has not been previously reported in the literature. Herein, we report a patient with Graves disease who developed postinfectious GBS during a course of methimazole-induced agranulocytosis.

Keywords

References

  1. Brent GA. Clinical practice: Graves' disease. N Engl J Med 2008;358:2594-2605. https://doi.org/10.1056/NEJMcp0801880
  2. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre syndrome: an update. J Clin Neurosci 2009;16:733-741. https://doi.org/10.1016/j.jocn.2008.08.033
  3. Guillain-Barre Syndrome Study Group. Guillain-Barre syndrome: an Italian multicentre case-control study: Guillain-Barre Syndrome Study Group. Neurol Sci 2000;21:229-234. https://doi.org/10.1007/s100720070081
  4. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008;7:939-950. https://doi.org/10.1016/S1474-4422(08)70215-1
  5. Geleijns K, Schreuder GM, Jacobs BC, et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 2005;64:44-49. https://doi.org/10.1212/01.WNL.0000148727.02732.01
  6. Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barre patients. J Neuroimmunol 2004;150:132-138. https://doi.org/10.1016/j.jneuroim.2004.01.003
  7. Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile-Orazio E. Long term disability and social status change after Guillain-Barre syndrome. J Neurol 2006;253:214-218. https://doi.org/10.1007/s00415-005-0958-x
  8. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome: Dutch Guillain-Barre Study Group. N Engl J Med 1992;326:1123-1129. https://doi.org/10.1056/NEJM199204233261705
  9. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-740. https://doi.org/10.1212/WNL.61.6.736

Cited by

  1. Thiamazole : Agranulocytosis and postinfectious Guillain-Barre syndrome: case report vol.1493, pp.1, 2014, https://doi.org/10.1007/s40278-014-9639-9
  2. Guillain–Barré Syndrome developing in a patient with Graves’ Disease vol.34, pp.1, 2013, https://doi.org/10.15605/jafes.034.01.17